Novartis Ag (NVSEF) Cash from Operations (2009 - 2025)

Novartis Ag has disclosed Cash from Operations across 10 years of filings, most recently posting 6664000000.0 for Q2 2025.

• Cash from Operations for Q2 2025 came in at 6664000000.0, up 36.7% year-over-year; the trailing twelve-month figure through Jun 2025 was 25212000000.0 (up 23.66% YoY), and the FY2025 annual result was 19144000000.0, up 8.66% from the prior year.
• Cash from Operations came in at 6664000000.0 for Q2 2025 at Novartis Ag, down from 7140000000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 7140000000.0 in Q4 2024 to a low of 3576000000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 5404000000.0 (2022), against an average of 5371222222.22.
• Across the five-year window, Cash from Operations fell 13.7% in 2022 and jumped 36.7% in 2025, its largest moves.
• Novartis Ag's Cash from Operations stood at 6262000000.0 in 2021, then retreated by 13.7% to 5404000000.0 in 2022, then increased by 20.89% to 6533000000.0 in 2023, then climbed by 9.29% to 7140000000.0 in 2024, then retreated by 6.67% to 6664000000.0 in 2025.
• The last three Cash from Operations figures came in at 6664000000.0 (Q2 2025), 7140000000.0 (Q4 2024), and 4875000000.0 (Q2 2024), per Business Quant data.